Ingenol Mebutate

巨大戟醇甲基丁烯酸酯

Report date: 2023/03/23 20:01:40
NMEFirst In Class

Base Information

Drug NameIngenol Mebutate
Drug Alias Nameingenoli mebutas巨大戟醇美布酯丁烯英酯mebutato de ingenolPicato +[8] 
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionApoptosis stimulantsImmunostimulantsProtein kinase C stimulants
TargetsProtein kinase C
Therapy Area/IndicationsKeratosis, SeborrheicKeratosisCheilitis +[9] 
Global Approved IndicationsKeratosis, Actinic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/01/23
Country/TerritoryCanadaUnited StatesNew Zealand +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLeo Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesLeo Pharma Inc
Inactive CompaniesPeplinActavis IncAssociacao Instituto Nacional De Cancer - Inca +[8] 
Active IndicationsKeratosis, Actinic
Inactive IndicationsKeratosis, SeborrheicKeratosisCheilitis +[8] 

Other Information

ATC CodeD06BX02
Related LinksWikipediaDrugBankKEGG